Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema.
Carter J PayneUrvi GuptaChristopher M MaatoukBlanche L KuoScott W PerkinsRishi P SinghKatherine E TalcottPublished in: Eye (London, England) (2024)
Many patients experienced improvements in BVA and CST over 12 months of treatment despite receiving less frequent anti-VEGF therapy than recommended in the pivotal trials. The present study showed that extended treatment intervals with bevacizumab were effective in preserving vision of many individuals with high baseline BVA.
Keyphrases
- vascular endothelial growth factor
- end stage renal disease
- type diabetes
- endothelial cells
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- metabolic syndrome
- mesenchymal stem cells
- combination therapy
- adipose tissue
- ultrasound guided
- weight loss
- wound healing
- patient reported
- cell therapy
- glycemic control